"I am pleased with Cytek’s strong revenue growth and continued execution throughout 2022," said Wenbin Jiang, CEO of Cytek Biosciences. "In addition to reporting strong financial results, we strengthened our organization with the addition of several executives to our team, and expanded our global presence. Today, we expanded our enterprise with the completed acquisition of Luminex’s Flow Cytometry and Imaging business and are excited to welcome this team to Cytek. Looking ahead to 2023, I am encouraged by our company’s position and confident in our continued success this year and beyond."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTKB:
- Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
- DiaSorin completes sale of Flow Cytometry & Imaging business to Cytek
- Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
- DiaSorin unit Luminex in pact with Cytek to sell FCI assets, no terms
- Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
